Cue Biopharma, Inc. 8-K

What Happened
Cue Biopharma, Inc. (CUE) announced in an 8-K filed June 3, 2026 that at its Special Meeting on June 1, 2026 stockholders approved the Cue Biopharma, Inc. 2026 Stock Incentive Plan (the “2026 Plan”) and, under Nasdaq rules, authorized issuance of common stock upon exercise of certain warrants issued in May 2026 in connection with a licensing transaction and related private placement. The 2026 Plan had been adopted by the Board subject to stockholder approval; a complete copy is attached as Exhibit 10.1 and the plan description is incorporated from the Proxy Statement filed May 21, 2026.

Key Details

• Special Meeting date: June 1, 2026; Form 8-K filed June 3, 2026.
• Proposal 1 (warrant-related issuance) vote: For 1,782,133; Against 113,311; Abstain 1,013.
• Proposal 2 (2026 Stock Incentive Plan) vote: For 1,261,296; Against 632,474; Abstain 2,687.
• Proposal 3 (adjournment if needed) vote: For 1,302,751; Against 582,084; Abstain 11,622 — not needed because Proposals 1 and 2 were approved.

Why It Matters
Approval of the 2026 Plan allows Cue to grant equity awards (options, restricted stock, etc.) to employees, directors and consultants under the new plan terms, which is a common tool for hiring and retention but can increase the company’s share count if awards are exercised. The Nasdaq-approved authorization to issue shares upon exercise of recently issued warrants clears a regulatory step tied to a May 2026 licensing/private placement transaction. Investors should note the actual dilution depends on future grant sizes and warrant exercises; the vote totals also show meaningful opposition to the plan (632,474 votes against), which may be of interest to governance-minded shareholders.